EMA Recommends Everolimus for Breast Cancer Ob.Gyn. News Digital Network The European Medicines Agency said June 22 that it had recommended an extension of indication for the cancer drug everolimus to treat hormone receptor–positive, HER2–negative advanced breast cancer. Everolimus (Afinitor, Novartis), already ... |
